Table 1 Demographic and clinical data of subjects participating to the study
Patients (n=126) | Controls (n=85) | p | |
|---|---|---|---|
Female:male (% female) | 105:19 (84) | 62:23 M (72.9) | 0.06 |
Age [median (IQR)], years | 51 (17) | 49 (20) | 0.11 |
Rheumatoid arthritis, n (%) | 31 (24.6) | ||
Systemic lupus erythematosus, n (%) | 31 (24.6) | ||
Psoriatic arthritis, n (%) | 26 (20.6) | ||
Undifferentiated connective tissue disease, n (%) | 11 (8.7) | ||
Ankylosing spondylitis, n (%) | 9 (7.1) | ||
Othera, n (%) | 18 (14.3) | ||
Glucocorticoids, n (%) | 28 (22.2) | ||
Hydroxychloroquine, n (%) | 30 (23.8) | ||
Immunosuppressive drugs | 70 (55.6) | ||
Methotrexate, n (%) | 21 (16.6) | ||
Other csDMARDs, n (%) | 10 (7.9) | ||
TNF inhibitors, n (%) | 34 (27) | ||
Other b/tsDMARDs, n (%) | 15 (11.9) | ||
Stopped ongoing therapy for vaccination, n (%) | 28 (22.2) |